InnoCare soficitinib meets Phase III endpoint in atopic dermatitis
InnoCare Pharma has announced that its oral TYK2 inhibitor soficitinib (ICP-332) met the primary endpoint in a registrational Phase III trial in patients with moderate-to-severe atopic dermatitis, with the company describing the improvement as both statistically significant and clinically meaningful.
The randomised, double-blind, placebo-controlled, multicentre study also met multiple secondary endpoints, InnoCare said, pointing to a consistent treatment effect across efficacy measures. The safety profile was reported as favourable and consistent with earlier clinical work, with no new safety signals identified. Full efficacy and safety data have not yet been released; the company intends to present detailed results at forthcoming international scientific congresses and in peer-reviewed publications.
The drug and its target
Soficitinib is a selective inhibitor of TYK2, a kinase that sits within the JAK-STAT signalling pathway and plays a role in the inflammatory cascades underpinning several autoimmune skin conditions. InnoCare is developing the compound across a broad dermatology portfolio that includes vitiligo, psoriasis, nodular prurigo and chronic spontaneous urticaria, in addition to atopic dermatitis. The company positions TYK2 selectivity as a potential differentiator, given that broader JAK inhibition has attracted regulatory scrutiny over cardiovascular and thromboembolic safety signals in recent years.
Dr Jasmine Cui, co-founder, chairwoman and chief executive of InnoCare, said the company plans to advance a regulatory filing for atopic dermatitis and continue Phase III work in other autoimmune indications. She did not specify a timeline for submission or a target market.
Market context and competitive landscape
Atopic dermatitis has become one of the most contested areas in immunology and dermatology. Bristol Myers Squibb's deucravacitinib, the first approved TYK2 inhibitor, received FDA approval in psoriasis in 2022 and is being studied in broader autoimmune indications, giving it a meaningful head start in the class. In atopic dermatitis specifically, InnoCare will face entrenched competition from dupilumab (Sanofi/Regeneron), which has become the standard of care in moderate-to-severe disease, as well as from approved JAK inhibitors including upadacitinib and abrocitinib. The commercial case for soficitinib will depend heavily on the full dataset, particularly head-to-head or indirect comparisons on efficacy benchmarks such as IGA response and EASI score reductions, which were not disclosed in this release.
The global burden of atopic dermatitis is substantial: the WHO Global Burden of Disease study estimates it affects up to 230 million people worldwide, and InnoCare cites nearly 70 million patients in China alone, a market the company is well positioned to address given its dual HKEX and SSE listing and established commercial infrastructure in major Chinese cities. Regulatory filing strategy across the China National Medical Products Administration and potentially the FDA or EMA will be a key question for investors to watch as the full data package becomes available.
InnoCare's broader pipeline includes three approved drugs, orelabrutinib, tafasitamab and zurletrectinib, giving the company a commercial base from which to fund the soficitinib regulatory programme. A positive Phase III readout is an important de-risking step, but the absence of detailed data means the market's full reaction will likely be deferred until congress presentations later this year.